000			01304 a2200337 4500
005			20250513000028.0
264		0	_c19830311
008			198303s 0 0 eng d
022			_a0028-3908
024	7		_a10.1016/0028-3908(82)90139-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aSperk, G
245	0	0	_aTissue levels of N-n-propylnorapomorphine after treatment with (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally long-acting prodrug active at central dopamine receptors. _h[electronic resource]
260			_bNeuropharmacology _cDec 1982
300			_a1311-6 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAnimals
650	0	4	_aApomorphine _xanalogs & derivatives
650	0	4	_aAporphines _xmetabolism
650	0	4	_aChromatography, High Pressure Liquid
650	0	4	_aHumans
650	0	4	_aRats
650	0	4	_aReceptors, Dopamine _xdrug effects
650	0	4	_aStereotyped Behavior _xdrug effects
700	1		_aCampbell, A
700	1		_aBaldessarini, R J
700	1		_aStoll, A
700	1		_aNeumeyer, J L
773	0		_tNeuropharmacology _gvol. 21 _gno. 12 _gp. 1311-6
856	4	0	_uhttps://doi.org/10.1016/0028-3908(82)90139-3 _zAvailable from publisher's website
999			_c6891175 _d6891175